{
  "schema_version": "1.3.1",
  "doc": {
    "doc_id": "bbe7cf74ef9b4e8de07ef4fc9748aa10",
    "title": "Morgan Stanley | RESEARCH",
    "source_uri": "25.9月 普通个人版/9.2 普通个人版/MS/Sichuan Kelun Pharmaceutical Co Ltd 2Q25 Hampered by Soft Demand Optimizing Product Mix to Counter ChallengesSichuan Kel_2025-08-31",
    "language": "en",
    "timestamps": {
      "ingested_at": "2025-10-27T00:56:41.725123",
      "extracted_at": "2025-10-27T00:56:41.725133"
    },
    "extraction_run": {
      "vision_model": "deepseek-ai/DeepSeek-OCR",
      "synthesis_model": "rule-based-engine",
      "pipeline_steps": [
        "ocr",
        "rule_extraction",
        "figure_vision"
      ],
      "processing_metadata": {
        "pages_processed": 9,
        "successful_pages": 9,
        "date": "2025-08-31",
        "publication": "25.9月 普通个人版/9.2 普通个人版/MS",
        "authors": [],
        "markdown_cleaning": {
          "removed_sections": 3,
          "removed_paragraphs": 6,
          "reduction_ratio": 0.1801632925102058
        },
        "input_relative_path": "25.9月 普通个人版/9.2 普通个人版/MS"
      }
    }
  },
  "passages": [
    {
      "passage_id": "d095481c354721de",
      "text": "August 31, 2025 05:55 PM GMT",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "5627b4367138906a",
      "text": "Unchanged Impact to our thesis",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "18d7ba831f111353",
      "text": "Modest shortfall Financial results versus consensus",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "d2115f7a14474216",
      "text": "Modest revision lower Direction of next 12-month consensus EPS",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "8cea0e155855d8c1",
      "text": "Source: Company data, Morgan Stanley Research",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "c8b48d8c0a333bd7",
      "text": "2Q revenue and recurring net profit were Rmb4.7bn (- 16% y/y), and Rmb42lmn (- 45% y/y), 7% and 28% below MSe, respectively. Soft demand for antibiotics was the main cause for the weak earnings performance; the company is countering the challenges with a mix shift to new products. Sac-TMT commercial progress seems on track with two additional major indications expected to be approved in the near term and potential NRDL inclusion in 2025.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "5db46d319aef55f7",
      "text": "decreases: In 1H25, sales of IV infusion, non-IV infusion generics, and antibiotics all saw sharp declines - generating Rmb3.8bn (- 20% y/y), Rmb1.6bn (- 23%) and Rmb2.3bn (- 30%), respectively, partly mitigated by sales of sac-TMT (Rmb310mn). GM was 44.2% in 2Q25, down 7.4pts y/y, due mainly to lower BD payments vs. 1H24 and a 6.1pt GM decrease in IV infusions.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "085e1eb015a18c92",
      "text": "Navigating challenges via product mix optimization: As demand for antibiotics has declined significantly, IV infusions saw prices fall 15% y/y and volume drop 10%, while market shares for double- and triple- chamber bags increased. Generics sales were affected by the 5th VBP. For bulk antibiotics, 6- APA price fell (- 20% y/y) and led to profit declining 18.3% in 2Q, while other intermediates prices were stable. Management sees the business stabilizing into 2026 with synthetic biology products ramping up soon.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "a53a9d813ea13b12",
      "text": "Innovative drugs progress on track: sNDAs for Sac- TMT in 2L EGFRm NSCLC, and 2H4/HER2- NSCLC, are under review; the drug is targeting NRDL inclusion this year, alongside two other new products (cetuximab biosimilar, PD- L1).",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "76dcf68c1dd5cf80",
      "text": "MORGAN STANLEY ASIA LIMITED+",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "57c74baab62cd057",
      "text": "Alexis Yan, CFA Equity Analyst",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "3e32290c4aa34b84",
      "text": "Sichuan Kelun Pharmaceutical Co Ltd (002422. SZ,",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "8d6e47a69d0fb5f1",
      "text": "China Healthcare | China",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "76825f8b1fbfaa8d",
      "text": "Up/downside to price target (%)",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "70538b843f52b819",
      "text": "Shr price, close (Aug 29, 2025)",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "babc3a57e2850abd",
      "text": "Avg daily trading value (mn)",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "a9e639bad1c35986",
      "text": "Revenue, net (Rmb mn)",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "2133afd85a1b3d26",
      "text": "Unless otherwise noted, all metrics are based on Morgan Stanley ModelWare",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "5a5c659cf7e16f49",
      "text": "\\(^{**}\\) Based on consensus methodology",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "94e232fd1fb60f0b",
      "text": "\\(^{**}\\) Consensus data is provided by Refinitiv Estimates",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "d49ea3cda9987153",
      "text": "\\(^{**}\\) Morgan Stanley Research estimates",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "a04d869151f6b321",
      "text": "Morgan Stanley does and seeks to do business with companies covered in Morgan Stanley Research. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of Morgan Stanley Research. Investors should consider Morgan Stanley Research as only a single factor in making their investment decision.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "13dbee0a0cc621b4",
      "text": "\\(^{**}\\) Analysts employed by non- U.S. affiliates are not registered with FINRA, may not be associated persons of the member and may not be subject to FINRA restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "981ec931fb578ca1",
      "text": "Base case, discounted cash flow methodology. We use this method because the company is FCF positive and mature, and generates sustainable earnings. We assume a WACC of \\(8.7\\%\\) (COE of \\(9.1\\%\\) ), and a steady growth rate of \\(3\\%\\) .",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "f7d55c99625919c9",
      "text": "We also use a SOTP- based approach to back out the implied holdco discount at \\(46\\%\\) , after deducting the value from IV infusion (15x P/E), generics (12x), current mkt cap of Chuanning, and Kelun Biotech.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "9f6bcb5e24e8d60a",
      "text": "Early product launches API price hikes",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "392cd1b432854ac5",
      "text": "- Continual rounds of centralized procurement coming to generic drug categories- Large infusions segment saturation with flat or declining revenue growth- Fluctuations in API pricing- Pipeline setbacks or failures of novel and generic drugs- Pace of drug launches not meeting market expectations",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "11998e3678f9cbaa",
      "text": "For important disclosures, stock price charts and equity rating histories regarding companies that are the subject of this report, please see the Morgan Stanley Research Disclosure Website at www.morganstanley.com/researchdisclosures, or contact your investment representative or Morgan Stanley Research at 1585 Broadway, (Attention: Research Management), New York, NY, 10036 USA.",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "d10f4daa009218ec",
      "text": "For valuation methodology and risks associated with any recommendation, rating or price target referenced in this research report, please contact the Client Support Team as follows: US/Canada +1 800 303- 2495; Hong Kong +852 2848- 5999; Latin America +1 718 754- 5444 (U.S.); London +44 (0)20- 7425- 8169; Singapore +65 6834- 6860; Sydney +61 (0)2- 9770- 1505; Tokyo +81 (0)3- 6836- 9000. Alternatively you may contact your investment representative or Morgan Stanley Research at 1585 Broadway, (Attention: Research Management), New York, NY 10036 USA.",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "63ea55becf4e269b",
      "text": "Morgan Stanley Research has been published in accordance with our conflict management policy, which is available at www.morganstanley.com/institutional/research/conflict policies. A Portuguese version of the policy can be found at www.morganstanley.com.br",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "b6ae0069702304ff",
      "text": "As of July 31, 2025, Morgan Stanley beneficially owned 1% or more of a class of common equity securities of the following companies covered in Morgan Stanley Research: Abbisko Cayman Ltd, China Traditional Chinese Medicine, Keymed Biosciences Inc., Pharmaron, Shandong Xinhua Pharmaceutical Co Ltd, Shenzhen Hepalink Pharmaceutical, WuXi AppTec Co Ltd, WuXi Biologics Cayman Inc, Yifeng Pharmacy Chain Co Ltd, Yixintang Pharmaceutical.",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "af764a7ff36cc23e",
      "text": "Within the last 12 months, Morgan Stanley managed or co- managed a public offering (or 144A offering) of securities of Akeso, Inc., Duality Biotherapeutics Inc, Everest Medicines Ltd, Hansoh Pharmaceutical Group Co Ltd, Innovent Biologics Inc, Jiangsu Hengrui, Keymed Biosciences Inc., Medtide, RemeGen Co., Ltd., VISEN Pharmaceuticals, WuXi AppTec Co Ltd, WuXi Biologics Cayman Inc, WuXi XDC Cayman Inc.",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "cb574321afe29bac",
      "text": "Within the last 12 months, Morgan Stanley has received compensation for investment banking services from Akeso, Inc., Duality Biotherapeutics Inc, Everest Medicines Ltd, Hansoh Pharmaceutical Group Co Ltd, Innovent Biologics Inc, Jiangsu Hengrui, Keymed Biosciences Inc., Medtide, Ping An Healthcare and Technology, RemeGen Co., Ltd., VISEN Pharmaceuticals, WuXi AppTec Co Ltd, WuXi Biologics Cayman Inc.",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "2263b5fcefd127fb",
      "text": "In the next 3 months, Morgan Stanley expects to receive or intends to seek compensation for investment banking services from 35Bio, Abbisko Cayman Ltd, Aier Eye Hospital Group, Akeso, Inc., Alibaba Health Information Technology, Angelalay Technology Inc, Beauty Farm Medical and Health Industry, China Medical System, CSCC Pharmaceutical Group Co Ltd, HUTCHMED (China) Ltd, Hygeia Healthcare Holdings Co., Ltd., Innovent Biologics Inc, Jiangsu Hengrui, Jixintang Pharmaceuticals, WuXi AppTec Co Ltd, WuXi Biologics Cayman Inc, WuXi XDC Cayman Inc.",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "3a64ff3777e51610",
      "text": "Within the last 12 months, Morgan Stanley has received compensation for products and services other than investment banking services from 35Bio, Adicon Holdings Ltd, Angelalay Technology Inc, Hygeia Healthcare Holdings Co., Ltd., Simcere Pharmaceutical Group, Sino Biopharmaceutical, The United Laboratories, WuXi AppTec Co Ltd, WuXi Biologics Cayman Inc, WuXi XDC Cayman Inc.",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "3a7c6ccfe5f39aa0",
      "text": "Within the last 12 months, Morgan Stanley has provided or is providing investment banking services to, or has an investment banking client relationship with, the following company: 35Bio, Abbisko Cayman Ltd, Aier Eye Hospital Group, Akeso, Inc., Alibaba Health Information Technology, Angelalay Technology Inc, Beauty Farm Medical and Health Industry, China Medical System, CSCC Pharmaceutical Group, Duality Biotherapeutics Inc, Everest Medicines Ltd, Fosun Pharmaceutical, Fu Shou Yuan International Group Ltd, Genscript Biotech Corporation, Hansoh Pharmaceutical Group Co Ltd, HUTCHMED (China) Ltd, Hygeia Healthcare Holdings Co., Ltd., Innovent Biologics Inc, Jixintang Pharmaceuticals, WuXi AppTec Co Ltd, WuXi Biologics Cayman Inc, Jixintang Pharmaceuticals, WuXi AppTec Co Ltd, WuXi BiologICS Cayman Inc, WuXi XDC Cayman Inc., Shanghai RAA5 Blood Products Co. Ltd., Simcere Pharmaceutical Group, Sino Biopharmaceutical, Sinopharm Group, VISEN Pharmaceuticals, WuXi AppTec Co Ltd, WuXi Biologics Cayman Inc, WuXi XDC Cayman Inc., Yifeng Pharmacy Chain Co Ltd, Yunnan Baiyao Group, Zylox-Tonbridge Medical Technology Co.",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "c94a4e7d7f586e8f",
      "text": "Within the last 12 months, Morgan Stanley has either provided or is providing non- investment banking, securities- related services to and/or in the past has entered into an agreement to provide services or has a client relationship with the following company: 35Bio, Abbisko Cayman Ltd, Adicon Holdings Ltd, Akeso, Inc., Angelalay Technology Inc, Duality Biotherapeutics Inc, HUTCHMED (China) Ltd, Hygeia Healthcare Holdings Co., Ltd., Innovent Biologics Inc, Jixintang Pharmaceuticals, WuXi AppTec Co Ltd, WuXi Biologics Cayman Inc, WuXi XDC Cayman Inc., Simcere Pharmaceutical Group, Sino Biopharmaceutical, The United Laboratories, VISEN Pharmaceuticals, WuXi AppTec Co Ltd, WuXi Biologics Cayman Inc, WuXi XDC Cayman Inc., Zylox-Tonbridge Medical Technology Co.",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "47a09a509962b3de",
      "text": "The quity rch alyts or sttig prily pible for the pration f Mgan Stl y Rech have rved cmnstion based upon vri fctrs, inclding qualit of rearch, nstor client fback, stock picking, competitive factors, firm revenues and overall investment banking revenues. Equity Research analysts or strategists compensation is not linked to investment banking or capital markets transactions performed by Morgan Stanley or the profitability or revenues of particular trading desks.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "0362245ba7de97a7",
      "text": "Morgan Stanley and its affliates do busines that relates to companies/instruments covered in Morgan Stanley Research, including market making, providing liquidity, fund management, commercial banking, extension of credit, investment services and investment banking. Morgan Stanley sells to and buys from customers the securities/instruments of companies covered in Morgan Stanley Research on a principal basis. Morgan Stanley may have a position in the debt of the Company or instruments discussed in this report. Morgan Stanley trades or may trade as principal in the debt securities (or in related derivatives) that are the subject of the debt research report.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "39f07b186e7a0034",
      "text": "Certain disclosures listed above are also for compliance with applicable regulations in non- US jurisdictions.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "4b011c5ac9aa949a",
      "text": "Morgan Stanley uses a relative rating system using terms such as Overweight, Equal- weight, Not- Rated or Underweight (see definitions below). Morgan Stanley does not assign ratings of Buy, Hold or Sell to the stocks we cover. Overweight, Equal- weight, Not- Rated and Underweight are not the equivalent of buy, hold and sell. Investors should carefully read the definitions of all ratings used in Morgan Stanley Research. In addition, since Morgan Stanley Research contains more complete information concerning the analyst's views, investors should carefully read Morgan Stanley Research, in its entirety, and not infer the contents from the rating alone. In any case, ratings (or research) should not be used or relied upon as investment advice. An investor's decision to buy or sell a stock should depend on individual circumstances (such as the investor's existing holdings) and other considerations.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "831838e03fdb04c0",
      "text": "(as of July 31, 2025)",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "87502364ed754651",
      "text": "The Stock Ratings described below apply to Morgan Stanley's Fundamental Equity Research and do not apply to Debt Research produced by the Firm. For disclosure purposes only (in accordance with FINRA requirements), we include the category headings of Buy, Hold, and Sell alongside our ratings of Overweight, Equal- weight, Not- Rated and Underweight. Morgan Stanley does not assign ratings of Buy, Hold or Sell to the stocks we cover. Overweight, Equal- weight, Not- Rated and Underweight are not the equivalent of buy, hold, and sell but represent recommended relative weightings (see definitions below). To satisfy regulatory requirements, we correspond Overweight, our most positive stock rating, with a buy recommendation; we correspond Equal- weight and Not- Rated to hold and Underweight to sell recommendations, respectively.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "9dac6b80cce6284d",
      "text": "Coverage UniverseInvestment Banking Clients (IBC)Other Material Investment Services Clients (MISC)Count% of TotalCount% of Total IBC% of Rating CategoryCount% of Total Other MISCStock Rating CategoryOverweight/Buy149540%37845%25%70141%Equal-weight/Hold160743%37445%23%76645%Not-Rated/Hold50%00%0%20%Underweight/Sell58816%8310%14%23614%Total3,6958351705",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "fc1a1667ec2f5142",
      "text": "Data include common stock and ADRs currently assigned ratings. Investment Banking Clients are companies from whom Morgan Stanley received investment banking compensation in the last 12 months. Due to rounding off of decimals, the percentages provided in the \\(\\%\\) of total' column may not add up to exactly 100 percent.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "707b17f2a53e0b4c",
      "text": "Overweight (O). The stock's total return is expected to exceed the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12- 18 months.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "9449ffb5300e7900",
      "text": "Equal- weight (E). The stock's total return is expected to be in line with the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12- 18 months.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "e375c73d3b523a97",
      "text": "Not- Rated (NR). Currently the analyst does not have adequate conviction about the stock's total return relative to the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12- 18 months.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "d11d00ff31b9921e",
      "text": "Underweight (U). The stock's total return is expected to be below the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12- 18 months.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "37e74c8a98a2b041",
      "text": "Unless otherwise specified, the time frame for price targets included in Morgan Stanley Research is 12 to 18 months.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "acc6c7f8cffccb06",
      "text": "Attractive (A): The analyst expects the performance of his or her industry coverage universe over the next 12- 18 months to be attractive vs. the relevant broad market benchmark, as indicated below.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "13cb761862daf8b2",
      "text": "In- Line (I): The analyst expects the performance of his or her industry coverage universe over the next 12- 18 months to be in line with the relevant broad market benchmark, as indicated below. Cautious (C): The analyst views the performance of his or her industry coverage universe over the next 12- 18 months with caution vs. the relevant broad market benchmark, as indicated below. Benchmarks for each region are as follows: North America - S&P 500; Latin America - relevant MSCI country index or MSCI Latin America Index; Europe - MSCI Europe; Japan - TOPIX; Asia - relevant MSCI country index or MSCI sub- regional index or MSCI AC Asia Pacific ex Japan Index.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "4f15a9f2c90b0bcf",
      "text": "Sichuan Kelun Pharmaceutical Co Ltd (002422.SZ) - As of 08/31/25 GMT in CNY Industry : China Healthcare",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "c49886fb90ee3523",
      "text": "Morgan Stanley Research policy is to update research reports as and when the Research Analyst and Research Management deem appropriate, based on developments with the issuer, the sector, or the market that may have a material impact on the research views or opinions stated therein. In addition, certain Research publications are intended to be updated on a regular periodic basis (weekly/monthly/quarterly/annual) and will ordinarily be updated with that frequency, unless the Research Analyst and Research Management determine that a different publication schedule is appropriate based on current conditions.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "bbdbd353fb5884c2",
      "text": "Morgan Stanley is not acting as a municipal advisor and the opinions or views contained herein are not intended to be, and do not constitute, advice within the meaning of Section 975 of the Dodd-Frank Wall Street Reform and Consumer Protection Act.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "1db3839e4e0865df",
      "text": "Morgan Stanley produces an equity research product called a \"Tactical Idea.\" Views contained in a \"Tactical Idea\" on a particular stock may be contrary to the recommendations or views expressed in research on the same stock. This may be the result of differing time horizons, methodologies, market events, or other factors. For all research available on a particular stock, please contact your sales representative or go to Matrix at http://www.morganstanley.com/matrix.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "7c8c64e63e75d87f",
      "text": "Morgan Stanley Research is provided to our clients through our proprietary research portal on Matrix and also distributed electronically by Morgan Stanley to clients. Certain, but not all, Morgan Stanley Research products are also made available to clients through third-party vendors or redistributed to clients through alternate electronic means as a convenience. For access to all available Morgan Stanley Research, please contact your sales representative or go to Matrix at http://www.morganstanley.com/matrix.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "f33d77def91e1cb4",
      "text": "Any access and/or use of Morgan Stanley Research is subject to Morgan Stanley's Terms of Use (http://www.morganstanley.com/terms.html). By accessing and/or using Morgan Stanley Research, you are indicating that you have read and agree to be bound by our Terms of Use (http://www.morganstanley.com/terms.html). In addition you consent to Morgan Stanley processing your personal data and using cookies in accordance with our Privacy Policy and our Global Cookies Policy (http://www.morganstanley.com/privacy_pledge.html), including for the purposes of setting your preferences and to collect readership data so that we can deliver better and more personalized service and products to you. To find out more information about how Morgan Stanley processes personal data, how we use cookies and how to reject cookies see our Privacy Policy and our Global Cookies Policy (http://www.morganstanley.com/privacy_pledge.html). If you do not agree to our Terms of Use and/or if you do not wish to provide your consent to Morgan Stanley processing your personal data or using cookies please do not access our research. Morgan Stanley Research does not provide individually tailored investment advice. Morgan Stanley Research has been prepared without regard to the circumstances and objectives of those who receive it. Morgan Stanley recommends that investors independently evaluate particular investments and strategies, and encourages investors to seek the advice of a financial adviser. The appropriateness of an investment or strategy will depend on an investor's circumstances and objectives. The securities, instruments, or strategies discussed in Morgan Stanley Research may not be suitable for all investors, and certain investors may not be eligible to purchase or participate in some or all of them. Morgan Stanley Research is not an offer to buy or sell or the solicitation of an offer to buy or sell any security/instrument or to participate in any particular trading strategy. The value of and income from your investments may vary because of changes",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "e99f83c513ea9d26",
      "text": "in interest rates, foreign exchange rates, default rates, prepayment rates, securities/instruments prices, market indexes, operational or financial conditions of companies or other factors. There may be time limitations on the exercise of options or other rights in securities/instruments transactions. Past performance is not necessarily a guide to future performance. Estimates of future performance are based on assumptions that may not be realized. If provided, and unless otherwise stated, the closing price on the cover page is that of the primary exchange for the subject company's securities/instruments.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "c0f466e8333daad9",
      "text": "The fixed income research analysts, strategists or economists principally responsible for the preparation of Morgan Stanley Research have received compensation based upon various factors, including quality, accuracy and value of research, firm profitability or revenues (which include fixed income trading and capital markets profitability or revenues), client feedback and competitive factors. Fixed Income Research analysts, strategists or economists' compensation is not linked to investment banking or capital markets transactions performed by Morgan Stanley or the profitability or revenues of particular trading desks.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "8721257dbd865c3f",
      "text": "The \"Important Regulatory Disclosures on Subject Companies\" section in Morgan Stanley Research lists all companies mentioned where Morgan Stanley owns \\(1\\%\\) or more of a class of common equity securities of the companies. For all other companies mentioned in Morgan Stanley Research, Morgan Stanley may have an investment of less than \\(1\\%\\) in securities/instruments or derivatives of securities/instruments of companies and may trade them in ways different from those discussed in Morgan Stanley Research. Employees of Morgan Stanley not involved in the preparation of Morgan Stanley Research may have investments in securities/instruments or derivatives of securities/instruments of companies mentioned and may trade them in ways different from those discussed in Morgan Stanley Research. Derivatives may be issued by Morgan Stanley or associated persons.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "d80029f87bcf6ab6",
      "text": "With the exception of information regarding Morgan Stanley, Morgan Stanley Research is based on public information. Morgan Stanley makes every effort to use reliable, comprehensive information, but we make no representation that it is accurate or complete. We have no obligation to tell you when opinions or information in Morgan Stanley Research change apart from when we intend to discontinue equity research coverage of a subject company. Facts and views presented in Morgan Stanley Research have not been reviewed by, and may not reflect information known to, professionals in other Morgan Stanley business areas, including investment banking personnel.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "d7b2984bfb1f7e24",
      "text": "Morgan Stanley Research personnel may participate in company events such as site visits and are generally prohibited from accepting payment by the company of associated expenses unless pre- approved by authorized members of Research management.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "6480ba9463f841ee",
      "text": "Morgan Stanley may make investment decisions that are inconsistent with the recommendations or views in this report.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "a4a2d7fb2760805a",
      "text": "To our readers based in Taiwan or trading in Taiwan securities/instruments: Information on securities/instruments that trade in Taiwan is distributed by Morgan Stanley Taiwan Limited (\"MSTL\"). Such information is for your reference only. The reader should independently evaluate the investment risks and is solely responsible for their investment decisions. Morgan Stanley Research may not be distributed to the public media or quoted or used by the public media without the express written consent of Morgan Stanley. Any non- customer reader within the scope of Article 7- 1 of the Taiwan Stock Exchange Recommendation Regulations accessing and/or receiving Morgan Stanley Research is not permitted to provide Morgan Stanley Research to any third party (including but not limited to related parties, affiliated companies and any other third parties) or engage in any activities regarding Morgan Stanley Research which may create or give the appearance of creating a conflict of interest. Information on securities/instruments that do not trade in Taiwan is for informational purposes only and is not to be construed as a recommendation or a solicitation to trade in such securities/instruments. MSTL may not execute transactions for clients in these securities/instruments.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "721ca40ac26581a0",
      "text": "Certain information in Morgan Stanley Research was sourced by employees of the Shanghai Representative Office of Morgan Stanley Asia Limited for the use of Morgan Stanley Asia Limited. Morgan Stanley is not incorporated under PRC law and the research in relation to this report is conducted outside the PRC. Morgan Stanley Research does not constitute an offer to sell or the solicitation of an offer to buy any securities in the PRC. PRC investors shall have the relevant qualifications to invest in such securities and shall be responsible for obtaining all relevant approvals, licenses, verifications and/or registrations from the relevant governmental authorities themselves. Neither this report nor any part of it is intended as, or shall constitute, provision of any consultancy or advisory service of securities investment as defined under PRC law. Such information is provided for your reference only.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "956a1eb1807d155c",
      "text": "Morgan Stanley Hong Kong Securities Limited is the liquidity provider/market maker for securities of Alibaba Health Information Technology, CSPC Pharmaceutical Group, Innovent Biologics Inc, JDH Health International Inc., Jinxin Fertility Group Ltd, Sino Biopharmaceutical, WuXi AppTec Co Ltd, WuXi Biologics Cayman Inc listed on the Stock Exchange of Hong Kong Limited. An updated list can be found on HKEx website: http://www.hkex.com.hk.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "93177608f9e6b41f",
      "text": "The information in Morgan Stanley Research is being communicated by Morgan Stanley & Co. International plc (DIFC Branch), regulated by the Dubai Financial Services Authority (the DFSA)",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "357db82d8ba7b520",
      "text": "or by Morgan Stanley & Co. International plc (ADGM Branch), regulated by the Financial Services Regulatory Authority Abu Dhabi (the FSRA), and is directed at Professional Clients only, as defined by the DFSA or the FSRA, respectively. The financial products or financial services to which this research relates will only be made available to a customer who we are satisfied meets the regulatory criteria of a Professional Client. A distribution of the different MS Research ratings or recommendations, in percentage terms for Investments in each sector covered, is available upon request from your sales representative.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "1c41df5dc2b2e1ae",
      "text": "The information in Morgan Stanley Research is being communicated by Morgan Stanley & Co. International plc (QFC Branch), regulated by the Qatar Financial Centre Regulatory Authority (the QFCRA), and is directed at business customers and market counterparties only and is not intended for Retail Customers as defined by the QFCRA.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "b956b5513a672e2d",
      "text": "As required by the Capital Markets Board of Turkey, investment information, comments and recommendations stated here, are not within the scope of investment advisory activity. Investment advisory service is provided exclusively to persons based on their risk and income preferences by the authorized firms. Comments and recommendations stated here are general in nature. These opinions may not fit to your financial status, risk and return preferences. For this reason, to make an investment decision by relying solely to this information stated here may not bring about outcomes that fit your expectations.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "b72aae733bc7ced7",
      "text": "The trademarks and service marks contained in Morgan Stanley Research are the property of their respective owners. Third- party data providers make no warranties or representations relating to the accuracy, completeness, or timeliness of the data they provide and shall not have liability for any damages relating to such data. The Global Industry Classification Standard (GICS) was developed by and is the exclusive property of MSCI and S&P.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "195e7c8e5c2c8e00",
      "text": "Morgan Stanley Research, or any portion thereof may not be reprinted, sold or redistributed without the written consent of Morgan Stanley. Indicators and trackers referenced in Morgan Stanley Research may not be used as, or treated as, a benchmark under Regulation EU 2016/101, or any other similar framework.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "cbfe9f5e79eec695",
      "text": "The issuers and/or fixed income products recommended or discussed in certain fixed income research reports may not be continuously followed. Accordingly, investors should regard those fixed income research reports as providing stand- alone analysis and should not expect continuing analysis or additional reports relating to such issuers and/or individual fixed income products. Morgan Stanley may hold, from time to time, material financial and commercial interests regarding the company subject to the Research report.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "772147f190f191ed",
      "text": "Registration granted by SEBI and certification from the National Institute of Securities Markets (NISM) in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "b7fcc3e312e1f2ec",
      "text": "COMPANY (TICKER)RATING (AS OF)PRICE* (08/29/2025)Alexis Yan, CFA3SBio (1530.HK)O (08/01/2025)HK$29.16Adicon Holdings Ltd (9860.HK)O (08/03/2023)HK$7.18Aier Eye Hospital Group (300015.SZ)U (07/08/2024)Rmb13.40Alibaba Health Information Technology (0241.HK)U (05/28/2025)HK$5.46Angelalign Technology Inc (6699.HK)E (03/17/2023)HK$72.45Beauty Farm Medical and Health Industry (2373.HK)E (02/20/2023)HK$35.10China Medical System (0867.HK)E (05/16/2025)HK$13.08China Resources Medical (1515.HK)U (03/17/2022)HK$3.65CSPC Pharmaceutical Group (1093.HK)O (08/15/2012)HK$10.07Dian Diagnostics Group Co Ltd (300244.SZ)E (07/12/2022)Rmb18.15Guangzhou Kingmed Diagnostics (603882.SS)U (07/08/2024)Rmb31.95Gushengtang Holdings Ltd (2273.HK)O (07/08/2024)HK$32.50Hansoh Pharmaceutical Group Co Ltd (3692.HK)O (07/16/2019)HK$36.02Huadong Medicine Co Ltd (000963.SZ)U (05/06/2024)Rmb44.30Hygeia Healthcare Holdings Co., Ltd. (6078.HK)O (07/30/2020)HK$14.96Imeik Technology Development Co Ltd (300896.SZ)E (02/06/2024)Rmb193.98JD Health International Inc. (6618.HK)E (05/28/2025)HK$62.80Jiangsu Hengrui (600276.SS)O (07/01/2025)Rmb66.23Jiangsu Hengrui (1276.HK)O (07/01/2025)HK$76.20Jinxin Fertility Group Ltd (1951.HK)U (07/14/2025)HK$2.88MicroPort Scientific Corp. (0853.HK)E (09/25/2023)HK$12.11Mindray Bio-Medical (300760.SZ)O (07/15/2020)Rmb242.79Peijia Medical Ltd (9996.HK)O (06/18/2020)HK$7.41Ping An Healthcare and Technology (1833.HK)E (05/28/2025)HK$20.66Shandong Weigao (1066.HK)E (07/10/2020)HK$5.87Shanghai United Imaging Healthcare Co (688271.SS)E (02/21/2025)Rmb141.80Shenzhen New Industries (300832.SZ)O (05/28/2024)Rmb62.42Sichuan Kelun Pharmaceutical Co Ltd (002422.SZ)U (05/16/2025)Rmb36.46Simcere Pharmaceutical Group (2096.HK)E (05/16/2025)HK$14.12Sino Biopharmaceutical (1177.HK)O (04/09/2019)HK$8.11",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "fd102e0e223d5cdd",
      "text": "Zylox-Tonbridge Medical Technology Co. (2190.HK) O (08/05/2021) HK\\\\$23.00",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "9bd3ba0cdf5e953d",
      "text": "Zylox-Tonbridge Medical Technology Co. (2190.HK)O (08/05/2021)HK\\\\$23.00Daisy ChengAsymchem Laboratories. Inc (002821.SZ)E (08/01/2025)Rmb106.92Asymchem Laboratories. Inc (6821.HK)E (06/06/2023)HK\\\\$91.25Genscript Biotech Corporation (1548.HK)O (08/14/2024)HK\\\\$17.20Hangzhou Tigermed Consulting (300347.SZ)O (08/01/2025)Rmb63.51Joinn Laboratories China Co Ltd (603127.SS)E (06/06/2023)Rmb31.39Joinn Laboratories China Co Ltd (6127.HK)E (02/26/2024)HK\\\\$21.40Pharmaron (3759.HK)O (09/25/2024)HK\\\\$20.90Pharmaron (300759.SZ)E (09/25/2024)Rmb30.26",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "a73dd64b4ea5edd9",
      "text": "Jack LinAbbisko Cayman Ltd (2256.HK)O (11/17/2021)HK\\\\$17.12Akeso, Inc. (9926.HK)O (05/28/2020)HK\\\\$155.70Duality Biotherapeutics Inc (9606.HK)O (05/22/2025)HK\\\\$315.60Everest Medicines Ltd (1952.HK)E (03/15/2024)HK\\\\$63.55HUTCHMED (China) Ltd (0013.HK)E (04/25/2023)HK\\\\$23.70HUTCHMED (China) Ltd (HCM.O)E (04/25/2023)US\\\\$15.01InnoCare Pharma Ltd (9969.HK)E (09/11/2023)HK\\\\$16.90Inventor Biologics Inc (1801.HK)O (12/03/2018)HK\\\\$96.85Keymed Biosciences Inc. (2162.HK)O (08/10/2021)HK\\\\$69.15RemeGen Co., Ltd. (9995.HK)E (05/08/2024)HK\\\\$98.15VISEN Pharmaceuticals (2561.HK)O (04/29/2025)HK\\\\$45.68Zai Lab Ltd (ZLAB.O)O (12/14/2023)US\\\\$33.10Zai Lab Ltd (9688.HK)O (12/14/2023)HK\\\\$25.62",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "b3853edab15c1cd7",
      "text": "Laurence TamApeloa Pharmaceutical Co Ltd (000739.SZ)O (02/28/2025)Rmb15.90Beijing Tongrentang (600085.SS)U (11/03/2014)Rmb35.68Beijing Tongrentang Chinese Medicine (3613.HK)O (01/14/2015)HK\\\\$9.16China National Accord Medicines Corp Ltd (000028.SZ)U (07/25/2022)Rmb25.80China Resources Pharmaceutical Group Ltd (3320.HK)O (06/16/2022)HK\\\\$4.88China Resources Sanjiu Medical &amp;amp; Pharma (000999.SZ)O (08/30/2019)Rmb30.43China Traditional Chinese Medicine (0570.HK)U (01/17/2025)HK\\\\$2.19DaShenLin Pharmaceutical (603233.SS)O (07/25/2022)Rmb16.86Dong E E Jiao Co. (000423.SZ)O (05/16/2024)Rmb51.88Fu Shou Yuan International Group Ltd (1448.HK)E (03/19/2025)HK\\\\$3.33Jiangzhong Pharmaceutical Co. Ltd. (600750.SS)O (02/08/2024)Rmb21.86Jointown Pharmaceutical Group (600998.SS)U (07/26/2021)Rmb5.12LBX Pharmacy Chain (603883.SS)O (03/14/2022)Rmb18.03Medtide (3880.HK)E (08/06/2025)HK\\\\$35.82Nanjing King-friend Biochemical (603707.SS)O (02/28/2025)Rmb11.32Shandong Xinhua Pharmaceutical Co Ltd (000756.SZ)U (02/28/2025)Rmb16.00Shanghai Pharmaceutical (601607.SS)E (08/17/2021)Rmb18.67Shanghai Pharmaceutical (2607.HK)O (08/17/2021)HK\\\\$12.35Shenzhen Hepalink Pharmaceutical (002399.SZ)U (06/16/2023)Rmb12.90Sinopharm Group (1099.HK)O (02/10/2023)HK\\\\$18.67Tasly Pharmaceutical Group Co. Ltd (600535.SS)E (07/19/2024)Rmb16.52The United Laboratories (3933.HK)E (06/13/2017)HK\\\\$15.34WuXi AppTec Co Ltd (603259.SS)O (01/17/2019)Rmb103.30WuXi AppTec Co Ltd (2359.HK)O (01/17/2019)HK\\\\$107.90WuXi Biologics Cayman Inc (2269.HK)O (07/17/2017)HK\\\\$33.20WuXi XDC Cayman Inc. (2268.HK)O (12/22/2023)HK\\\\$56.60Yantai Dongcheng Biochemicals Co Ltd (002675.SZ)E (02/28/2025)Rmb16.71Yifeng Pharmacy Chain Co Ltd (603939.SS)O (07/25/2022)Rmb23.74Yixintang Pharmaceutical (002727.SZ)E (07/25/2022)Rmb14.69Yunnan Baiyao Group (000538.SZ)O (10/11/2021)Rmb57.58",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "678611a55b268d13",
      "text": "Zhangzhou Pientzehuang Pharmaceutical (600436.SS)U (01/21/2022)Rmb209.22Zhejiang Hisun Pharmaceutical Co. Ltd. (600267.SS)U (06/01/2023)Rmb10.80Zhejiang Huahai Pharmaceutical Co. Ltd. (600521.SS)O (06/01/2023)Rmb24.17Zhejiang Jiuzhou Pharmaceutical Co Ltd (603456.SS)E (02/28/2025)Rmb18.09Zhejiang Medicine Co. Ltd. (600216.SS)E (02/28/2025)Rmb15.66Yanru TaoBeijing Tiantan Biological Products Corp (600161.SS)O (05/27/2024)Rmb20.05China Resources Boya Bio-pharmaceutical (300294.SZ)E (05/27/2024)Rmb26.61Fosun Pharmaceutical (2196.HK)E (01/17/2025)HK&#36;21.74Fosun Pharmaceutical (600196.SS)E (04/06/2020)Rmb28.84Hualan Biological Engineering Inc. (002007.SZ)U (03/17/2022)Rmb17.10Pacific Shuanglin Bio-pharmacy (000403.SZ)O (05/27/2024)Rmb17.70Shanghai RAAS Blood Products Co. Ltd. (002252.SZ)U (05/27/2024)Rmb6.88",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "8b8c5c54dd512278",
      "text": "Stock Ratings are subject to change. Please see latest research for each company. \\\\* Historical prices are not split adjusted.",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "a78e74000e755fd7",
      "text": "\\(①\\) 2025 Morgan Stanley",
      "page": 8,
      "section": null
    }
  ],
  "entities": [
    {
      "entity_id": "5dc8f59a60c48918",
      "name": "ADGM Branch",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "6e2b07ce0caec706",
      "name": "Abbisko Cayman",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "01ac4e3f7cbdbebe",
      "name": "Abbisko Cayman Ltd",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "ed49291dd8535b70",
      "name": "Abu Dhabi",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "8997a3424c395e08",
      "name": "Accord Medicines",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "610edadada2d2f24",
      "name": "Adicon Holdings",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "7883d3a2091d0aa9",
      "name": "Adicon Holdings Ltd",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "8ffc189db47b47e1",
      "name": "Aier Eye",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "8f57874f321fefef",
      "name": "Aier Eye Hospital Group",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "541f0a4e8e8d62f5",
      "name": "Alexis Yan",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "8a05af9b2ade215b",
      "name": "Alibaba Health",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "a9935cd77e910646",
      "name": "America Index",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "c1dfd762e0cb5b5f",
      "name": "Analyst\n\nYanru",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "e8600890357193e9",
      "name": "Analyst Industry",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "264f4569dd91d68d",
      "name": "Analyst Stock",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "93bd628f469ad947",
      "name": "Angelalay Technology",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "51c384da33f85021",
      "name": "Angelalay Technology Inc",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "94aad02912e08575",
      "name": "Angelalign Technology",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "49e17a0dfbf57697",
      "name": "Angelalign Technology Inc",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "9aceb1da860e21ae",
      "name": "Apeloa Pharmaceutical",
      "type": "company",
      "aliases": []
    }
  ],
  "data": {
    "figures": [],
    "tables": [],
    "numerical_data": [
      {
        "num_id": "7139de1bf24c5e23",
        "value": 0.16,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ta, Morgan Stanley Research ## Key Takeaways 2Q revenue and recurring net profit were Rmb4.7bn (- 16% y/y), and Rmb42lmn (- 45% y/y), 7% and 28% below MSe, respectively. Soft demand for antibiotics wa",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "940ba1acc36f4861",
        "value": 0.45,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "h ## Key Takeaways 2Q revenue and recurring net profit were Rmb4.7bn (- 16% y/y), and Rmb42lmn (- 45% y/y), 7% and 28% below MSe, respectively. Soft demand for antibiotics was the main cause for the w",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "51b4c0a7bb88a966",
        "value": 0.07,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "Takeaways 2Q revenue and recurring net profit were Rmb4.7bn (- 16% y/y), and Rmb42lmn (- 45% y/y), 7% and 28% below MSe, respectively. Soft demand for antibiotics was the main cause for the weak earni",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "1a35a89e347c1700",
        "value": 0.28,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ys 2Q revenue and recurring net profit were Rmb4.7bn (- 16% y/y), and Rmb42lmn (- 45% y/y), 7% and 28% below MSe, respectively. Soft demand for antibiotics was the main cause for the weak earnings per",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "4f327c230b2b8715",
        "value": 0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "infusion, non-IV infusion generics, and antibiotics all saw sharp declines - generating Rmb3.8bn (- 20% y/y), Rmb1.6bn (- 23%) and Rmb2.3bn (- 30%), respectively, partly mitigated by sales of sac-TMT ",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "4c54db5495759377",
        "value": 0.23,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ion generics, and antibiotics all saw sharp declines - generating Rmb3.8bn (- 20% y/y), Rmb1.6bn (- 23%) and Rmb2.3bn (- 30%), respectively, partly mitigated by sales of sac-TMT (Rmb310mn). GM was 44.",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "4a8cd330a1f602f9",
        "value": 0.3,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ibiotics all saw sharp declines - generating Rmb3.8bn (- 20% y/y), Rmb1.6bn (- 23%) and Rmb2.3bn (- 30%), respectively, partly mitigated by sales of sac-TMT (Rmb310mn). GM was 44.2% in 2Q25, down 7.4p",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "2057b0ab7e360ca6",
        "value": 0.442,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "(- 23%) and Rmb2.3bn (- 30%), respectively, partly mitigated by sales of sac-TMT (Rmb310mn). GM was 44.2% in 2Q25, down 7.4pts y/y, due mainly to lower BD payments vs. 1H24 and a 6.1pt GM decrease in ",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "a27866f5e9c8246b",
        "value": 0.15,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ix optimization: As demand for antibiotics has declined significantly, IV infusions saw prices fall 15% y/y and volume drop 10%, while market shares for double- and triple- chamber bags increased. Gen",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "d0314c6160aff616",
        "value": 0.1,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "nd for antibiotics has declined significantly, IV infusions saw prices fall 15% y/y and volume drop 10%, while market shares for double- and triple- chamber bags increased. Generics sales were affecte",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "7c60e462209fd2c9",
        "value": 0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "increased. Generics sales were affected by the 5th VBP. For bulk antibiotics, 6- APA price fell (- 20% y/y) and led to profit declining 18.3% in 2Q, while other intermediates prices were stable. Manag",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "09f8a2393712c981",
        "value": 0.183,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ted by the 5th VBP. For bulk antibiotics, 6- APA price fell (- 20% y/y) and led to profit declining 18.3% in 2Q, while other intermediates prices were stable. Management sees the business stabilizing ",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "0ff13667a116ec5b",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "Regulatory Disclosures on Subject Companies As of July 31, 2025, Morgan Stanley beneficially owned 1% or more of a class of common equity securities of the following companies covered in Morgan Stanle",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "ce299f7a318bc3f6",
        "value": 0.4,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Overweight/Buy</td><td>1495</td><td>40%</td><td>378</td><td>45%</td><td>25%</td><td>701</td><td>41%</td></tr><tr><td>Equal-weight/Hold</",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "4e322b1efd50a8ad",
        "value": 0.45,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td></td><td></td><td></td></tr><tr><td>Overweight/Buy</td><td>1495</td><td>40%</td><td>378</td><td>45%</td><td>25%</td><td>701</td><td>41%</td></tr><tr><td>Equal-weight/Hold</td><td>1607</td><td>43%<",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "7957f8cb57526131",
        "value": 0.25,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "></td><td></td></tr><tr><td>Overweight/Buy</td><td>1495</td><td>40%</td><td>378</td><td>45%</td><td>25%</td><td>701</td><td>41%</td></tr><tr><td>Equal-weight/Hold</td><td>1607</td><td>43%</td><td>374<",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "cf0d0ecdf4d39807",
        "value": 0.41,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>Overweight/Buy</td><td>1495</td><td>40%</td><td>378</td><td>45%</td><td>25%</td><td>701</td><td>41%</td></tr><tr><td>Equal-weight/Hold</td><td>1607</td><td>43%</td><td>374</td><td>45%</td><td>23%<",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "7dab2f4674ddaa66",
        "value": 0.43,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>45%</td><td>25%</td><td>701</td><td>41%</td></tr><tr><td>Equal-weight/Hold</td><td>1607</td><td>43%</td><td>374</td><td>45%</td><td>23%</td><td>766</td><td>45%</td></tr><tr><td>Not-Rated/Hold</td>",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "531a000a31be27c1",
        "value": 0.45,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>701</td><td>41%</td></tr><tr><td>Equal-weight/Hold</td><td>1607</td><td>43%</td><td>374</td><td>45%</td><td>23%</td><td>766</td><td>45%</td></tr><tr><td>Not-Rated/Hold</td><td>5</td><td>0%</td><td",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "073787a77c2d6d76",
        "value": 0.23,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>41%</td></tr><tr><td>Equal-weight/Hold</td><td>1607</td><td>43%</td><td>374</td><td>45%</td><td>23%</td><td>766</td><td>45%</td></tr><tr><td>Not-Rated/Hold</td><td>5</td><td>0%</td><td>0</td><td>0",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "758495611d5c5d6a",
        "value": 0.45,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">Equal-weight/Hold</td><td>1607</td><td>43%</td><td>374</td><td>45%</td><td>23%</td><td>766</td><td>45%</td></tr><tr><td>Not-Rated/Hold</td><td>5</td><td>0%</td><td>0</td><td>0%</td><td>0%</td><td>2</",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "8a5ac033eba6e81e",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "4</td><td>45%</td><td>23%</td><td>766</td><td>45%</td></tr><tr><td>Not-Rated/Hold</td><td>5</td><td>0%</td><td>0</td><td>0%</td><td>0%</td><td>2</td><td>0%</td></tr><tr><td>Underweight/Sell</td><td>58",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "ee10b5c03c9ba921",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">23%</td><td>766</td><td>45%</td></tr><tr><td>Not-Rated/Hold</td><td>5</td><td>0%</td><td>0</td><td>0%</td><td>0%</td><td>2</td><td>0%</td></tr><tr><td>Underweight/Sell</td><td>588</td><td>16%</td><td",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "1090547cacd4be0a",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>766</td><td>45%</td></tr><tr><td>Not-Rated/Hold</td><td>5</td><td>0%</td><td>0</td><td>0%</td><td>0%</td><td>2</td><td>0%</td></tr><tr><td>Underweight/Sell</td><td>588</td><td>16%</td><td>83</td><td",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "962681e59dc91074",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "></tr><tr><td>Not-Rated/Hold</td><td>5</td><td>0%</td><td>0</td><td>0%</td><td>0%</td><td>2</td><td>0%</td></tr><tr><td>Underweight/Sell</td><td>588</td><td>16%</td><td>83</td><td>10%</td><td>14%</td>",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "64b6a57c3a9fe871",
        "value": 0.16,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">0</td><td>0%</td><td>0%</td><td>2</td><td>0%</td></tr><tr><td>Underweight/Sell</td><td>588</td><td>16%</td><td>83</td><td>10%</td><td>14%</td><td>236</td><td>14%</td></tr><tr><td>Total</td><td>3,695<",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "d69e57373df99e48",
        "value": 0.1,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "%</td><td>2</td><td>0%</td></tr><tr><td>Underweight/Sell</td><td>588</td><td>16%</td><td>83</td><td>10%</td><td>14%</td><td>236</td><td>14%</td></tr><tr><td>Total</td><td>3,695</td><td></td><td>835</t",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "3073a1730b74bd72",
        "value": 0.14,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>0%</td></tr><tr><td>Underweight/Sell</td><td>588</td><td>16%</td><td>83</td><td>10%</td><td>14%</td><td>236</td><td>14%</td></tr><tr><td>Total</td><td>3,695</td><td></td><td>835</td><td></td><",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "997bb9bd8f1420f5",
        "value": 0.14,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>Underweight/Sell</td><td>588</td><td>16%</td><td>83</td><td>10%</td><td>14%</td><td>236</td><td>14%</td></tr><tr><td>Total</td><td>3,695</td><td></td><td>835</td><td></td><td></td><td>1705</td><td",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "8d930c7462891b79",
        "value": 29.16,
        "unit": "$",
        "metric_type": "currency",
        "context": "Alexis Yan, CFA</td><td></td><td></td></tr><tr><td>3SBio (1530.HK)</td><td>O (08/01/2025)</td><td>HK$29.16</td></tr><tr><td>Adicon Holdings Ltd (9860.HK)</td><td>O (08/03/2023)</td><td>HK$7.18</td></t",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "b28fced243934e7c",
        "value": 7.18,
        "unit": "$",
        "metric_type": "currency",
        "context": "5)</td><td>HK$29.16</td></tr><tr><td>Adicon Holdings Ltd (9860.HK)</td><td>O (08/03/2023)</td><td>HK$7.18</td></tr><tr><td>Aier Eye Hospital Group (300015.SZ)</td><td>U (07/08/2024)</td><td>Rmb13.40</",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "a75fa7c9b848e123",
        "value": 5.46,
        "unit": "$",
        "metric_type": "currency",
        "context": "0</td></tr><tr><td>Alibaba Health Information Technology (0241.HK)</td><td>U (05/28/2025)</td><td>HK$5.46</td></tr><tr><td>Angelalign Technology Inc (6699.HK)</td><td>E (03/17/2023)</td><td>HK$72.45</",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "4561ceaae97cf6ca",
        "value": 72.45,
        "unit": "$",
        "metric_type": "currency",
        "context": "d><td>HK$5.46</td></tr><tr><td>Angelalign Technology Inc (6699.HK)</td><td>E (03/17/2023)</td><td>HK$72.45</td></tr><tr><td>Beauty Farm Medical and Health Industry (2373.HK)</td><td>E (02/20/2023)</td",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "2b20139efe732a2e",
        "value": 35.1,
        "unit": "$",
        "metric_type": "currency",
        "context": "/td></tr><tr><td>Beauty Farm Medical and Health Industry (2373.HK)</td><td>E (02/20/2023)</td><td>HK$35.10</td></tr><tr><td>China Medical System (0867.HK)</td><td>E (05/16/2025)</td><td>HK$13.08</td><",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "9e0f8988aa10b3e5",
        "value": 13.08,
        "unit": "$",
        "metric_type": "currency",
        "context": ")</td><td>HK$35.10</td></tr><tr><td>China Medical System (0867.HK)</td><td>E (05/16/2025)</td><td>HK$13.08</td></tr><tr><td>China Resources Medical (1515.HK)</td><td>U (03/17/2022)</td><td>HK$3.65</td",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "fd1afeb29b94c405",
        "value": 3.65,
        "unit": "$",
        "metric_type": "currency",
        "context": "td><td>HK$13.08</td></tr><tr><td>China Resources Medical (1515.HK)</td><td>U (03/17/2022)</td><td>HK$3.65</td></tr><tr><td>CSPC Pharmaceutical Group (1093.HK)</td><td>O (08/15/2012)</td><td>HK$10.07</",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "2aee8058e32561e0",
        "value": 10.07,
        "unit": "$",
        "metric_type": "currency",
        "context": "d><td>HK$3.65</td></tr><tr><td>CSPC Pharmaceutical Group (1093.HK)</td><td>O (08/15/2012)</td><td>HK$10.07</td></tr><tr><td>Dian Diagnostics Group Co Ltd (300244.SZ)</td><td>E (07/12/2022)</td><td>Rmb",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "1e65c66ee369f76b",
        "value": 32.5,
        "unit": "$",
        "metric_type": "currency",
        "context": "d><td>Rmb31.95</td></tr><tr><td>Gushengtang Holdings Ltd (2273.HK)</td><td>O (07/08/2024)</td><td>HK$32.50</td></tr><tr><td>Hansoh Pharmaceutical Group Co Ltd (3692.HK)</td><td>O (07/16/2019)</td><td>",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "1c0994703da9730f",
        "value": 36.02,
        "unit": "$",
        "metric_type": "currency",
        "context": "2.50</td></tr><tr><td>Hansoh Pharmaceutical Group Co Ltd (3692.HK)</td><td>O (07/16/2019)</td><td>HK$36.02</td></tr><tr><td>Huadong Medicine Co Ltd (000963.SZ)</td><td>U (05/06/2024)</td><td>Rmb44.30<",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "9077bd4f04841efe",
        "value": 14.96,
        "unit": "$",
        "metric_type": "currency",
        "context": "30</td></tr><tr><td>Hygeia Healthcare Holdings Co., Ltd. (6078.HK)</td><td>O (07/30/2020)</td><td>HK$14.96</td></tr><tr><td>Imeik Technology Development Co Ltd (300896.SZ)</td><td>E (02/06/2024)</td><",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "ca1fdfbe0658e8ec",
        "value": 62.8,
        "unit": "$",
        "metric_type": "currency",
        "context": ">Rmb193.98</td></tr><tr><td>JD Health International Inc. (6618.HK)</td><td>E (05/28/2025)</td><td>HK$62.80</td></tr><tr><td>Jiangsu Hengrui (600276.SS)</td><td>O (07/01/2025)</td><td>Rmb66.23</td></tr",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "68fd618591aee7cf",
        "value": 76.2,
        "unit": "$",
        "metric_type": "currency",
        "context": "/2025)</td><td>Rmb66.23</td></tr><tr><td>Jiangsu Hengrui (1276.HK)</td><td>O (07/01/2025)</td><td>HK$76.20</td></tr><tr><td>Jinxin Fertility Group Ltd (1951.HK)</td><td>U (07/14/2025)</td><td>HK$2.88<",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "65a65173bca7aaca",
        "value": 2.88,
        "unit": "$",
        "metric_type": "currency",
        "context": "<td>HK$76.20</td></tr><tr><td>Jinxin Fertility Group Ltd (1951.HK)</td><td>U (07/14/2025)</td><td>HK$2.88</td></tr><tr><td>MicroPort Scientific Corp. (0853.HK)</td><td>E (09/25/2023)</td><td>HK$12.11<",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "a1111ce6645eba99",
        "value": 12.11,
        "unit": "$",
        "metric_type": "currency",
        "context": "><td>HK$2.88</td></tr><tr><td>MicroPort Scientific Corp. (0853.HK)</td><td>E (09/25/2023)</td><td>HK$12.11</td></tr><tr><td>Mindray Bio-Medical (300760.SZ)</td><td>O (07/15/2020)</td><td>Rmb242.79</td",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "de63199a739c14cb",
        "value": 7.41,
        "unit": "$",
        "metric_type": "currency",
        "context": "0)</td><td>Rmb242.79</td></tr><tr><td>Peijia Medical Ltd (9996.HK)</td><td>O (06/18/2020)</td><td>HK$7.41</td></tr><tr><td>Ping An Healthcare and Technology (1833.HK)</td><td>E (05/28/2025)</td><td>HK",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "fdea55e41a438cb6",
        "value": 20.66,
        "unit": "$",
        "metric_type": "currency",
        "context": "$7.41</td></tr><tr><td>Ping An Healthcare and Technology (1833.HK)</td><td>E (05/28/2025)</td><td>HK$20.66</td></tr><tr><td>Shandong Weigao (1066.HK)</td><td>E (07/10/2020)</td><td>HK$5.87</td></tr><t",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "6925bef10d4b070d",
        "value": 5.87,
        "unit": "$",
        "metric_type": "currency",
        "context": "/2025)</td><td>HK$20.66</td></tr><tr><td>Shandong Weigao (1066.HK)</td><td>E (07/10/2020)</td><td>HK$5.87</td></tr><tr><td>Shanghai United Imaging Healthcare Co (688271.SS)</td><td>E (02/21/2025)</td>",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "07ff1d1594b31592",
        "value": 14.12,
        "unit": "$",
        "metric_type": "currency",
        "context": "d>Rmb36.46</td></tr><tr><td>Simcere Pharmaceutical Group (2096.HK)</td><td>E (05/16/2025)</td><td>HK$14.12</td></tr><tr><td>Sino Biopharmaceutical (1177.HK)</td><td>O (04/09/2019)</td><td>HK$8.11</td>",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "c4b5e6501dbef79a",
        "value": 8.11,
        "unit": "$",
        "metric_type": "currency",
        "context": "/td><td>HK$14.12</td></tr><tr><td>Sino Biopharmaceutical (1177.HK)</td><td>O (04/09/2019)</td><td>HK$8.11</td></tr></table><｜end▁of▁sentence｜>",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "bcc9688a4a9a8eef",
        "value": 23.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "Zylox-Tonbridge Medical Technology Co. (2190.HK) O (08/05/2021) HK\\\\$23.00 <table><tr><td>Zylox-Tonbridge Medical Technology Co. (2190.HK)</td><td>O (08/05/2021)</td><td>HK\\\\$",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "63c33aed76279a30",
        "value": 23.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "<table><tr><td>Zylox-Tonbridge Medical Technology Co. (2190.HK)</td><td>O (08/05/2021)</td><td>HK\\\\$23.00</td></tr><tr><td>Daisy Cheng</td><td></td><td></td></tr><tr><td>Asymchem Laboratories. Inc (00",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "19d15ffa75d6a3c2",
        "value": 91.25,
        "unit": "$",
        "metric_type": "currency",
        "context": ">Rmb106.92</td></tr><tr><td>Asymchem Laboratories. Inc (6821.HK)</td><td>E (06/06/2023)</td><td>HK\\\\$91.25</td></tr><tr><td>Genscript Biotech Corporation (1548.HK)</td><td>O (08/14/2024)</td><td>HK\\\\$",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "2a599ce32208e142",
        "value": 17.2,
        "unit": "$",
        "metric_type": "currency",
        "context": "\\$91.25</td></tr><tr><td>Genscript Biotech Corporation (1548.HK)</td><td>O (08/14/2024)</td><td>HK\\\\$17.20</td></tr><tr><td>Hangzhou Tigermed Consulting (300347.SZ)</td><td>O (08/01/2025)</td><td>Rmb6",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "ee39026599692b12",
        "value": 21.4,
        "unit": "$",
        "metric_type": "currency",
        "context": "31.39</td></tr><tr><td>Joinn Laboratories China Co Ltd (6127.HK)</td><td>E (02/26/2024)</td><td>HK\\\\$21.40</td></tr><tr><td>Pharmaron (3759.HK)</td><td>O (09/25/2024)</td><td>HK\\\\$20.90</td></tr><tr><",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "54cd04010eb2e86b",
        "value": 20.9,
        "unit": "$",
        "metric_type": "currency",
        "context": "26/2024)</td><td>HK\\\\$21.40</td></tr><tr><td>Pharmaron (3759.HK)</td><td>O (09/25/2024)</td><td>HK\\\\$20.90</td></tr><tr><td>Pharmaron (300759.SZ)</td><td>E (09/25/2024)</td><td>Rmb30.26</td></tr></tab",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "b03d142872125a12",
        "value": 17.12,
        "unit": "$",
        "metric_type": "currency",
        "context": "</td><td></td><td></td></tr><tr><td>Abbisko Cayman Ltd (2256.HK)</td><td>O (11/17/2021)</td><td>HK\\\\$17.12</td></tr><tr><td>Akeso, Inc. (9926.HK)</td><td>O (05/28/2020)</td><td>HK\\\\$155.70</td></tr><t",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "50be38ef62f6ebe9",
        "value": 155.7,
        "unit": "$",
        "metric_type": "currency",
        "context": "/2021)</td><td>HK\\\\$17.12</td></tr><tr><td>Akeso, Inc. (9926.HK)</td><td>O (05/28/2020)</td><td>HK\\\\$155.70</td></tr><tr><td>Duality Biotherapeutics Inc (9606.HK)</td><td>O (05/22/2025)</td><td>HK\\\\$3",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "a99d42ff2126214f",
        "value": 315.6,
        "unit": "$",
        "metric_type": "currency",
        "context": "\\\\$155.70</td></tr><tr><td>Duality Biotherapeutics Inc (9606.HK)</td><td>O (05/22/2025)</td><td>HK\\\\$315.60</td></tr><tr><td>Everest Medicines Ltd (1952.HK)</td><td>E (03/15/2024)</td><td>HK\\\\$63.55</",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "415579bc44e3181a",
        "value": 63.55,
        "unit": "$",
        "metric_type": "currency",
        "context": "<td>HK\\\\$315.60</td></tr><tr><td>Everest Medicines Ltd (1952.HK)</td><td>E (03/15/2024)</td><td>HK\\\\$63.55</td></tr><tr><td>HUTCHMED (China) Ltd (0013.HK)</td><td>E (04/25/2023)</td><td>HK\\\\$23.70</td",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "f64b04b61fd95a71",
        "value": 23.7,
        "unit": "$",
        "metric_type": "currency",
        "context": "d><td>HK\\\\$63.55</td></tr><tr><td>HUTCHMED (China) Ltd (0013.HK)</td><td>E (04/25/2023)</td><td>HK\\\\$23.70</td></tr><tr><td>HUTCHMED (China) Ltd (HCM.O)</td><td>E (04/25/2023)</td><td>US\\\\$15.01</td><",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "5fc756bc5730c4c2",
        "value": 15.01,
        "unit": "$",
        "metric_type": "currency",
        "context": "/td><td>HK\\\\$23.70</td></tr><tr><td>HUTCHMED (China) Ltd (HCM.O)</td><td>E (04/25/2023)</td><td>US\\\\$15.01</td></tr><tr><td>InnoCare Pharma Ltd (9969.HK)</td><td>E (09/11/2023)</td><td>HK\\\\$16.90</td>",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "7a4ee1fc1ddbe4a1",
        "value": 16.9,
        "unit": "$",
        "metric_type": "currency",
        "context": "td><td>US\\\\$15.01</td></tr><tr><td>InnoCare Pharma Ltd (9969.HK)</td><td>E (09/11/2023)</td><td>HK\\\\$16.90</td></tr><tr><td>Inventor Biologics Inc (1801.HK)</td><td>O (12/03/2018)</td><td>HK\\\\$96.85</",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "a3ee399883f38809",
        "value": 96.85,
        "unit": "$",
        "metric_type": "currency",
        "context": "<td>HK\\\\$16.90</td></tr><tr><td>Inventor Biologics Inc (1801.HK)</td><td>O (12/03/2018)</td><td>HK\\\\$96.85</td></tr><tr><td>Keymed Biosciences Inc. (2162.HK)</td><td>O (08/10/2021)</td><td>HK\\\\$69.15<",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "c0342971ecde1f4e",
        "value": 69.15,
        "unit": "$",
        "metric_type": "currency",
        "context": "td>HK\\\\$96.85</td></tr><tr><td>Keymed Biosciences Inc. (2162.HK)</td><td>O (08/10/2021)</td><td>HK\\\\$69.15</td></tr><tr><td>RemeGen Co., Ltd. (9995.HK)</td><td>E (05/08/2024)</td><td>HK\\\\$98.15</td></",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "53fd74357ff176a5",
        "value": 98.15,
        "unit": "$",
        "metric_type": "currency",
        "context": "</td><td>HK\\\\$69.15</td></tr><tr><td>RemeGen Co., Ltd. (9995.HK)</td><td>E (05/08/2024)</td><td>HK\\\\$98.15</td></tr><tr><td>VISEN Pharmaceuticals (2561.HK)</td><td>O (04/29/2025)</td><td>HK\\\\$45.68</t",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "c70cce35d6a52da6",
        "value": 45.68,
        "unit": "$",
        "metric_type": "currency",
        "context": "><td>HK\\\\$98.15</td></tr><tr><td>VISEN Pharmaceuticals (2561.HK)</td><td>O (04/29/2025)</td><td>HK\\\\$45.68</td></tr><tr><td>Zai Lab Ltd (ZLAB.O)</td><td>O (12/14/2023)</td><td>US\\\\$33.10</td></tr><tr>",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "a6eed6b32991e455",
        "value": 33.1,
        "unit": "$",
        "metric_type": "currency",
        "context": "9/2025)</td><td>HK\\\\$45.68</td></tr><tr><td>Zai Lab Ltd (ZLAB.O)</td><td>O (12/14/2023)</td><td>US\\\\$33.10</td></tr><tr><td>Zai Lab Ltd (9688.HK)</td><td>O (12/14/2023)</td><td>HK\\\\$25.62</td></tr></t",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "e68d4854a983bea5",
        "value": 25.62,
        "unit": "$",
        "metric_type": "currency",
        "context": "/2023)</td><td>US\\\\$33.10</td></tr><tr><td>Zai Lab Ltd (9688.HK)</td><td>O (12/14/2023)</td><td>HK\\\\$25.62</td></tr></table> <table><tr><td>Laurence Tam</td><td></td><td></td></tr><tr><td>Apeloa Pharm",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "b55dfb9ec0494db2",
        "value": 9.16,
        "unit": "$",
        "metric_type": "currency",
        "context": "</td></tr><tr><td>Beijing Tongrentang Chinese Medicine (3613.HK)</td><td>O (01/14/2015)</td><td>HK\\\\$9.16</td></tr><tr><td>China National Accord Medicines Corp Ltd (000028.SZ)</td><td>U (07/25/2022)</",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "3415cefdc2a39b5f",
        "value": 4.88,
        "unit": "$",
        "metric_type": "currency",
        "context": "></tr><tr><td>China Resources Pharmaceutical Group Ltd (3320.HK)</td><td>O (06/16/2022)</td><td>HK\\\\$4.88</td></tr><tr><td>China Resources Sanjiu Medical &amp;amp; Pharma (000999.SZ)</td><td>O (08/30/",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "de6932dc68f3d37b",
        "value": 2.19,
        "unit": "$",
        "metric_type": "currency",
        "context": "43</td></tr><tr><td>China Traditional Chinese Medicine (0570.HK)</td><td>U (01/17/2025)</td><td>HK\\\\$2.19</td></tr><tr><td>DaShenLin Pharmaceutical (603233.SS)</td><td>O (07/25/2022)</td><td>Rmb16.86<",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "e18670f7556190e7",
        "value": 3.33,
        "unit": "$",
        "metric_type": "currency",
        "context": "</td></tr><tr><td>Fu Shou Yuan International Group Ltd (1448.HK)</td><td>E (03/19/2025)</td><td>HK\\\\$3.33</td></tr><tr><td>Jiangzhong Pharmaceutical Co. Ltd. (600750.SS)</td><td>O (02/08/2024)</td><td",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "a73c2a6b6e795658",
        "value": 35.82,
        "unit": "$",
        "metric_type": "currency",
        "context": "(03/14/2022)</td><td>Rmb18.03</td></tr><tr><td>Medtide (3880.HK)</td><td>E (08/06/2025)</td><td>HK\\\\$35.82</td></tr><tr><td>Nanjing King-friend Biochemical (603707.SS)</td><td>O (02/28/2025)</td><td>R",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "a5effd914c11e8b1",
        "value": 12.35,
        "unit": "$",
        "metric_type": "currency",
        "context": "><td>Rmb18.67</td></tr><tr><td>Shanghai Pharmaceutical (2607.HK)</td><td>O (08/17/2021)</td><td>HK\\\\$12.35</td></tr><tr><td>Shenzhen Hepalink Pharmaceutical (002399.SZ)</td><td>U (06/16/2023)</td><td>",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "f17cba3722ab2c9a",
        "value": 18.67,
        "unit": "$",
        "metric_type": "currency",
        "context": "023)</td><td>Rmb12.90</td></tr><tr><td>Sinopharm Group (1099.HK)</td><td>O (02/10/2023)</td><td>HK\\\\$18.67</td></tr><tr><td>Tasly Pharmaceutical Group Co. Ltd (600535.SS)</td><td>E (07/19/2024)</td><t",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "824d041231eccd3d",
        "value": 15.34,
        "unit": "$",
        "metric_type": "currency",
        "context": "><td>Rmb16.52</td></tr><tr><td>The United Laboratories (3933.HK)</td><td>E (06/13/2017)</td><td>HK\\\\$15.34</td></tr><tr><td>WuXi AppTec Co Ltd (603259.SS)</td><td>O (01/17/2019)</td><td>Rmb103.30</td>",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "178b6a167f3d9bf8",
        "value": 107.9,
        "unit": "$",
        "metric_type": "currency",
        "context": "</td><td>Rmb103.30</td></tr><tr><td>WuXi AppTec Co Ltd (2359.HK)</td><td>O (01/17/2019)</td><td>HK\\\\$107.90</td></tr><tr><td>WuXi Biologics Cayman Inc (2269.HK)</td><td>O (07/17/2017)</td><td>HK\\\\$33.",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "acc6a448e4e21110",
        "value": 33.2,
        "unit": "$",
        "metric_type": "currency",
        "context": "HK\\\\$107.90</td></tr><tr><td>WuXi Biologics Cayman Inc (2269.HK)</td><td>O (07/17/2017)</td><td>HK\\\\$33.20</td></tr><tr><td>WuXi XDC Cayman Inc. (2268.HK)</td><td>O (12/22/2023)</td><td>HK\\\\$56.60</td",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "597495376c0a02d1",
        "value": 56.6,
        "unit": "$",
        "metric_type": "currency",
        "context": "d><td>HK\\\\$33.20</td></tr><tr><td>WuXi XDC Cayman Inc. (2268.HK)</td><td>O (12/22/2023)</td><td>HK\\\\$56.60</td></tr><tr><td>Yantai Dongcheng Biochemicals Co Ltd (002675.SZ)</td><td>E (02/28/2025)</td>",
        "provenance": {
          "page": 7
        }
      }
    ],
    "claims": [],
    "relations": [],
    "extraction_summary": {
      "figures_count": 0,
      "tables_count": 0,
      "numerical_data_count": 79,
      "passages_count": 83,
      "entities_count": 20
    }
  }
}